Table 2. Risk according to baseline Risk Assessment (APTIII definition) in patients with no baseline CVD, hypertension or diabetes.

		Estrogen + Progestin								Estrogen alone
		Placebo		Treatment					P value for interaction	Placebo		Treatment
		Controls	Cases	Controls	Cases	OR	lower CL	upper CL		Controls	Cases	Controls	Cases	OR	lower CL	upper CL	P value for interaction
MBS, meeting three or	No	100	23	137	34	1.13	(0.61,	2.13)	0.173	58	17	51	13	0.75	(0.30,	1.86)	0.123
more criteria, APTIII definition	Yes	56	18	39	30	2.26	(1.05,	4.85)		44	11	35	20	2.11	(0.81,	5.48)
Waist > 35 inches (80 cm	No	95	26	115	36	1.22	(0.66,	2.26)	0.541	49	17	46	14	0.75	(0.30,	1.87)	0.114
for Asian and American	Yes
Indian)		60	15	61	28	1.66	(0.78,	3.53)		55	11	41	19	2.16	(0.84,	5.52)
Elevated blood pressure	No	80	15	111	34	1.86	(0.90,	3.83)	0.392	55	10	45	11	1.39	(0.50,	3.92)	0.822
>=130/85	Yes	76	26	66	30	1.21	(0.62,	2.34)		49	18	42	22	1.20	(0.51,	2.79)
Elevated triglycerides >	No	97	21	130	35	1.38	(0.72,	2.61)	0.773	62	17	43	15	1.13	(0.48,	2.68)	0.699
150 mg/dL	Yes	59	20	47	29	1.59	(0.76,	3.31)		42	11	44	18	1.46	(0.55,	3.88)
reduced HDL < 50 mg/dL	No	97	19	124	31	1.37	(0.70,	2.67)	0.753	64	12	52	12	1.32	(0.52,	3.39)	0.693
	Yes	59	22	52	33	1.60	(0.80,	3.20)		39	16	35	20	1.02	(0.41,	2.55)
Elevated fasting glucose	No	89	24	127	33	0.95	(0.51,	1.77)	0.057	59	16	54	24	1.51	(0.67,	3.41)	0.401
>= 100 mg/dL	Yes	67	17	50	30	2.46	(1.15,	5.24)		44	12	32	9	0.85	(0.28,	2.54)

		Combined Trials
	Placebo			Treatment
		Controls	Cases	Controls	Cases	OR	lower CL	upper CL	P value for interaction
MBS, meeting three or	No	158	40	188	47	0.97	(0.58,	1.61)	0.032
more criteria, APTIII	Yes
definition		100	29	74	50	2.26	(1.26,	4.07)
Waist > 35 inches (80 cm	No	144	43	161	50	1.03	(0.62,	1.70)	0.120
for Asian and American	Yes
Indian)		115	26	102	47	1.93	(1.08,	3.44)
Elevated blood pressure	No	135	25	156	45	1.70	(0.95,	3.05)	0.406
>=130/85	Yes	125	44	108	52	1.22	(0.73,	2.04)
Elevated triglycerides >	No	159	38	173	50	1.24	(0.75,	2.04)	0.569
150 mg/dL	Yes	101	31	91	47	1.54	(0.87,	2.75)
reduced HDL < 50 mg/dL	No	161	31	176	43	1.33	(0.78,	2.28)	0.895
	Yes	98	38	87	53	1.40	(0.81,	2.42)
Elevated fasting glucose	No	148	40	181	57	1.12	(0.69,	1.83)	0.234
>= 100 mg/dL	Yes	111	29	82	39	1.80	(0.99,	3.29)

Participants with baseline history of CHD, stroke, angina, re-vascularization, DVT, PE, diabetes, and hypertension were excluded from analysis Adjusted for baseline smoking, age, education, hysterectomy status, and lipid lowering medication.